The article details FDA's Accelerated Drug Development, including guidelines, definition of serious conditions, strategies, features, and withdrawal reasons.
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Rozlytrek (entrectinib), a treatment for adult and adolescent patients whose cancers have the specific genetic defect ...